the ratio of 13 CO 2 / 12 CO 2 in exhaled breath. 3 In the presence of H. pylori, ingested ¹³C-urea is metabolized to 13 CO 2 . The resulting 13 CO 2 / 12 CO 2 ratio is compared with baseline values obtained before ingestion of the labeled urea. UBTs have high accuracy and reproducibility because they are functional tests that essentially sample the entire stomach. These tests are not prone to the same level of sampling error as biopsy-based tests, and false-positive results are uncommon. 4 The sensitivity and specificity of the breath test range from 90% to 100% and, in most cases, it is above 95%. [5] [6] [7] UBTs are the preferred method for epidemiological studies, screening dyspeptic patients, and assessing eradication or recurrence of the infection after treatment. 3, [8] [9] [10] A major disadvantage of the 13 C-UBT is the inconvenience related to the 13 CO 2 analysis. In most medical centers, there is a need for collecting, storing, and transporting the samples to a central laboratory that is equipped with an isotope ratio mass spectrometer. This makes UBTs inconvenient to both the patient and physician.
A Food and Drug Administration (FDA)-cleared continuous UBT (using a nasal cannula) using the BreathID ® Hp (Exalenz Bioscience Ltd, Modiin, Israel) provides several unique advantageous features. Instead of collecting and analyzing discrete breath samples, breath samples are continually evaluated, providing excellent accuracy (>99%) and enabling shortened breath testing procedures. Moreover, test results are available in real time for decision-making at the point of care. 11, 12 A user-friendly interface for operation and point-of-care testing is another advantage.
Although the BreathID ® Hp Lab System has the advantage of real-time point-of-care analyses, using this system has its disadvantages: patients need to be present at the site where this system is located. In addition, only one patient's breath can be measured at a time. This can limit the number of tests that can be done in a short time period. Using bags to collect breath samples allows accumulation of up to 10 sets of breath collection bags for up to 2 weeks. The BreathID ® Hp Lab System performs automated analyses sequentially. This system may be located in a central laboratory or the system can be installed on-site. Its user-friendly interface, compact design, maintenance-free use, compatibility to lab information management system (LIMS), low cost compared to mass spectrometer, and automated operation make it an ideal method for H.pylori testing. Testing of each set of bags takes approximately 5 min. This study was aimed at validating the breath sampling bag test method in comparison to a composite reference standard of H. pylori status, comprising a combination of a histological examination for H. pylori and a rapid urease test (RUT).
Methods

Subjects
We determined the diagnostic accuracy of the BreathID ® Hp Lab System in two prospectively enrolled sets of patients: initial diagnosis and posteradication follow-up. This clinical study was conducted at 13 clinical sites in the USA and in Israel. Study participants were men and women 18 years of age or older who had a clinical indication for H. pylori testing for either initial diagnosis or posteradication therapy verification (provided that their initial positive H. pylori diagnosis was confirmed through endoscopic biopsy). The study was approved by each clinical site's Institutional Review Board or an Independent Ethics Committee (in the USA only) and was registered at clinicaltrials.gov. Each subject provided informed consent prior to participating in the study.
Subjects were included in the initial diagnosis cohort if they had not received H. pylori treatments in the preceding 18 months and had not been tested for H. pylori within the 6 months prior to enrollment. Subjects were included in the posteradication therapy cohort if they had biopsy documentation of H. pylori infection prior to eradication therapy and had documentation of receiving H. pylori eradication therapy within 6 months and completion of therapy at least 6 weeks prior to the UBT.
Evaluation of H. pylori status Each subject was evaluated for H. pylori status by three diagnostic methods: histology, RUT, and UBT. For histopathology and RUT, each subject underwent an EGD according to the standard clinical practice at each site. If the UBT was planned to be performed on the same day as the endoscopy, the subjects performed the UBT before the EGD. The American College of Gastroenterology guidelines 1 recommend that a journals.sagepub.com/home/cmg 3 minimum of three biopsies be obtained (one from the angularis, one from the greater curvature of the corpus, and one from the greater curvature of the antrum) in order to maximize the diagnostic yield. 13 In this study, all biopsies were taken in duplicate (for histology and RUT) resulting in a minimum of six biopsies: two from the angularis, two from the greater curvature of the corpus, and two from the greater curvature of the antrum. Biopsies from each of the three sites within the stomach were analyzed by histology and RUT.
Histopathology: at least three biopsy specimens were fixed with formalin, sectioned at a thickness of 4-5 μm and then stained with hematoxylin and eosin and by an immunohistochemistry (IHC) assay (Novacastra lyophilized polyclonal, product code NCL-HPp, purchased from Leica). The stain was performed on a Ventana ULTRA slide staining system. All slides were examined and analyzed by an experienced pathologist at a central laboratory.
RUT: at least three biopsy specimens, (similar to the ones taken by for histology) were analyzed onsite for urease activity after 1 h, with an FDAcleared RUT (Pronto Dry ® , Warsaw, Poland) according to the manufacturer's instructions. The principle of the RUT test is as follows: if H. pylori is present in the gastric biopsy, it secretes the urease which results in breakdown of urea, which in turn causes the pH to increase, and the color of the pH indicator changes.
The UBT was performed within 1 week before or after the EGD. After fasting for at least 1 h, each participant filled two bags prior to the UBT test (baseline bags A DOB ⩾ 5 indicates an H. pylori infection which was determined by preliminary studies (described in the Lab System's publicly available package insert). The BreathID ® Hp Lab System contains an autosampler unit and has an application to control the process that can measure up to 10 sets of bags consecutively and automatically within approximately 25 min. The bags are produced by Exalenz Bioscience Ltd. They are made of a printed flexible laminate LDPE 80 having a oneway valve and their volume (capacity) is 240 ml.
Based on the test results, the subject's status was classified as H. pylori positive, H. pylori negative, or non-evaluable. These results were compared to the classification results obtained by histopathology, RUT, and both combined (composite) according to FDA classification guidelines. 14 RUT was considered positive if any of the samples showed a positive result. If all samples were negative, the patient was classified as RUT negative. All biopsy samples were assessed together to provide a conclusive histology outcome. A subject was considered histologically positive when at least one of the samples showed positive IHC. Only if all three biopsy samples were IHC negative, the patient was classified as histologically negative. Finally, to determine if a patient was positive or negative when combining the RUT and histology results, FDA guidelines were used. 14 If a patient was in the initial diagnosis cohort, only if there were concordant results between RUT and histology was the patient classified as positive or negative. Patients with discordant results were considered non-evaluable. For a patient in the post-eradication cohort, any positive outcome (RUT, histology or both) would render the subject's classification as positive. Only if both RUT and histology were found to be negative would the post-eradication cohort patient be classified as negative.
The investigators remained blinded to the UBT results and the central pathology readings throughout the whole study to ensure that the patients would only be treated based on current clinical practice, without introducing bias from the UBT results or the central pathology laboratory assessments and to avoid any potential enrollment bias. Patient management decisions were made according to standard medical practice based on local testing results.
Stability of breath samples over time
To assess the stability of the breath samples in the breath sample bags, each pair of breath sample bags (before and after ingestion), obtained from the initial diagnosis cohort, was analyzed at a different time point up to 14 days after collection (on two different reading days). The stability was evaluated by the fact that the 13 CO 2 / 12 CO 2 ratio did not change between the different bag's sampling. The first evaluable set of bags was used for the primary analysis. The second set of bags was collected and measured in order to assess the stability of the breath samples over time.
Reproducibility and repeatability results
Analytical studies were conducted to evaluate the reproducibility and precision (repeatability) of the results of the 13 C-UBT for measurements by different technicians and using different BreathID ® Hp Lab System, or when testing was done on different days and at different sites, and on samples that were stored up to 14 days at different temperature and humidity conditions. Three different gas isotope pairs were used with DOB values of 3.3, 6.4, and 15.5, as determined via a bench study. Reproducibility was assessed by two operators who were asked to operate each of three BreathID ® Hp Lab System at three different sites for 5 days in order to measure the DOB values for samples from each of the three batches. Standard deviation (SD) was calculated. The package insert states that the SD is less than the natural variability of the DOB measurement, which is defined in the device specification as 1 DOB for results under 5 DOB and 20% for results over 5 DOB.
Statistical analysis
All statistical analyses were performed after the study was completed, and the database was locked. Statistical programming and analyses were performed using SAS ® version 9.4. The results are presented in two-way contingency tables. The exact binomial distribution was used to calculate the lower and upper limits of the 95% confidence intervals (CI) for the performance statistics.
Results
A total of 189 subjects (78 women and 111 men, mean age 48.4 ± 14.9 years) were included in the initial diagnosis cohort. The post-eradication therapy cohort included 68 subjects (43 women and 25 men, mean age 49.7 ± 15.3 years). The characteristics of the study participants are summarized in Table 1 . In both groups, the most V Richter, JO Gonzalez et al.
journals.sagepub.com/home/cmg 5 common indications for EGD were heartburn and abdominal pain. The most common endoscopic finding was antral erythema.
Comparison of 13 (Table 2) .
Comparing the breath test to RUT only showed a sensitivity of 88.1% (95% CI: 75.0%, 94.8%) and a specificity of 95.2% (95% CI: 90.5%, 97.7%), and the kappa (95% CI) was 0.82 (Table  3) . These results are slightly lower than the other sensitivity and specificity results presented in this study. This is mainly due to the addition of the subjects that were classified as non-evaluable per the composite reference standard when the RUT and histology results were discordant. In the majority of those cases, the breath test agreed with the histology results and not with the RUT result. RUT results can sometimes be ambiguous due to the need to determine a clear change in color by visual inspection. Comparing the breath test to the histology classification showed a sensitivity of 97.6% (95% CI: 87.7%, 99.6%) and a specificity of 98.0% (95% CI: 94.2%, 99.3%), and kappa (95% CI) was 0.94 (Table 3) . This subject classified as a false negative had a breath test result that was close to the predefined clinical cut-off value of 5 DOB, but they were classified as positive per the composite reference standard based on a positive histology assessment despite the fact that all three RUT samples produced a negative result.
The overall agreement between the UBT diagnosis and the biopsy diagnosis in the post-eradication therapy cohort was 98.5% (95% CI: 92.1%, 100.0%) and the kappa (95% CI) was 0.95. The sensitivity of the breath test in this cohort was 92.3% (95% CI: 66.7%, 98.6%) and its specificity was 100.0% (95% CI: 93.5%, 100.0%; Table 3 ).
Comparing the breath test to RUT only showed a sensitivity of 100.0% (95% CI: 74.1%, 100.0%) and a specificity of 98.3% (95% CI: 90.7%, 99.7%), and kappa (95% CI) 0.95. Comparing the breath test to histology demonstrated a sensitivity of 92.3% (95% CI: 66.7%, 98.6%) and a specificity of 100.0% (95% CI: 93.5%, 100.0%), and kappa (95% CI) 0.95; Table 3 ). Safety. Overall, there were a total of four adverse events in the initial diagnosis cohort and one adverse event in the post-eradication therapy cohort: one subject had a cyst found on the epiglottis, one had a gastric ulcer, two patients had nausea for approximately 2 min after drinking the breath test mixture and one felt lightheaded due to fasting for the EGD procedure. None of them were serious or severe, and none were related to the study device. Hence, the test procedure itself was found to be very safe and well-tolerated by all subjects. 
Stability of breath samples over time.
Reproducibility and repeatability results.
The results demonstrated that the SD and overall reproducibility of the results of the 13 C-UBT were stable over different batches for both the operator, the devices, and between days. The reproducibility SD was 0.65 or less for all batches, and the between days, devices and operators SD was 0.66 or less in all cases; this is less than the natural variability of the DOB measurement (Table 4) . Repeatability was assessed by measuring the DOB values for samples from each of the three batches twice a day for 12 days. The results demonstrated that the SD and overall repeatability were stable over different batches and different days. The repeatability SD was 0.64 or less and the overall between-days SD was 0.72 or less; this is less than the natural variability of the DOB measurement (Table 5) . Breath sample bags were stored at two different storage conditions representing the two extreme temperatures of the recommended storage range (15°C and 35°C) and at the high limit for the recommended relative humidity (70%). The DOB values for samples from each storage condition were measured on the BreathID ® Hp Lab System seven times during 14 consecutive days for each storage condition, specifically on days 2, 4, 8, 9, 10, 11, and 14. The results demonstrated that the SD and overall repeatability were stable over different batches, days, and storage conditions. The overall repeatability SD and the between days precision SD were 0.60 or less; this is less than the natural variability of the DOB measurement (Table 6) .
Discussion
Active H. pylori testing is the preferred modality according to guidelines by the American College of Gastroenterology, the American Gastroenterological Association, and the European and Japanese societies in the test-and-treat approach to dyspepsia. . Finally, this is a reliable system, user-friendly with touch-screen operation, maintenance free, compact, and the system has availability to be connected to a laboratory Lab Information Management Software (LIMS) system.
The optimal 13 C-UBT conditions for diagnosing H. pylori infection are still being perfected. The optimal diagnostic cut-off point discriminating between positive and negative 13 C-UBT results is still a controversial issue. Therefore, the results for 13 C-UBT often affect the diagnostic accuracy when the results are very close to the cutoff as at the onset of the infection or when the level lies in a so-called gray zone. 3 The BreathID ® Hp Lab System shares with its predicate device the same underlying technology, test substrate, and diagnostic capabilities. Both the subject and predicate systems use molecular correlation spectroscopy (MCS) technology and measure the ratio of 13 CO 2 / 12 CO 2 in exhaled breath prior to and after administration of the test substrate ( 13 C-Urea). MCS technology measures the light absorbance of the sample by infrared spectrometry; this correlates to the CO 2 concentrations of the different carbon isotpoes in the breath sample. The output results from both systems are the DOB, and a positive/negative determination is based on the same assay cutoff (⩾5 DOB). Indeed, this study has shown that the cutoff of 5 DOB for the BreathID ® Hp Lab System is precise and accurate when compared to the gold standard (EGD biopsy results). However, when assessing gastric biopsies, it should be noted that RUT is considered to be less accurate than IHC assessments. 16 Indeed, comparison of the UBT results in our study, to RUT and histology, respectively, revealed higher agreement with IHC, a finding consistent with a recent publication. 17 There are several limitations to this study. First, the breath test was not compared to culture which is one of the recommended reference standards, as the efforts needed to insure proper conditions for culture growing were very difficult logistically to arrange in a clinical study and prone to human error. The FDA accepts a reference composite score using RUT and histology alone. Furthermore, the RUT test, whose results are determined by change in color of the substrate, can be interpreted differently by different users in borderline cases
